
Elicio Therapeutics and FDA Agree on Regulatory Strategy for ELI-002: A New Milestone in Drug Development
Encouraging News from the FDA: Potential Breakthroughs with ELI-002 In a recent development, Eli Lilly and Company, a leading pharmaceutical company, announced that they have received supportive feedback from the Food and Drug Administration (FDA) regarding the key elements of the potential Phase 3 study design for ELI-002. This news comes as a significant step…